Pfizer announced that its antibody-drug conjugate Padcev, when combined with the immunotherapy Keytruda, significantly extended survival in patients with invasive bladder cancer who were ineligible for cisplatin chemotherapy. The EV-303 trial showed improved event-free survival and overall survival compared to surgery alone, marking an important advancement in bladder cancer treatment. The drug was acquired through Pfizer's $43 billion purchase of Seagen and is marketed jointly with Astellas.